Research ArticleArticle
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles
C.-C. Chan, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, A. W. Ford-Hutchinson, M. J. Forrest, J. Y. Gauthier, R. Gordon, M. Gresser, J. Guay, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mancini, G. P. O’Neill, M. Ouellet, D. Patrick, M. D. Percival, H. Perrier, P. Prasit, I. Rodger, P. Tagari, M. Therien, P. Vickers, D. Visco, Z. Wang, J. Webb, E. Wong, L.-J. Xu, R. N. Young, R. Zamboni and D. Riendeau
Journal of Pharmacology and Experimental Therapeutics August 1999, 290 (2) 551-560;
C.-C. Chan
S. Boyce
C. Brideau
S. Charleson
W. Cromlish
D. Ethier
J. Evans
A. W. Ford-Hutchinson
M. J. Forrest
J. Y. Gauthier
R. Gordon
M. Gresser
J. Guay
S. Kargman
B. Kennedy
Y. Leblanc
S. Leger
J. Mancini
G. P. O’Neill
M. Ouellet
D. Patrick
M. D. Percival
H. Perrier
P. Prasit
I. Rodger
P. Tagari
M. Therien
P. Vickers
D. Visco
Z. Wang
J. Webb
E. Wong
L.-J. Xu
R. N. Young
R. Zamboni

JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 2
1 Aug 1999
Research ArticleArticle
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles
C.-C. Chan, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, A. W. Ford-Hutchinson, M. J. Forrest, J. Y. Gauthier, R. Gordon, M. Gresser, J. Guay, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mancini, G. P. O’Neill, M. Ouellet, D. Patrick, M. D. Percival, H. Perrier, P. Prasit, I. Rodger, P. Tagari, M. Therien, P. Vickers, D. Visco, Z. Wang, J. Webb, E. Wong, L.-J. Xu, R. N. Young, R. Zamboni and D. Riendeau
Journal of Pharmacology and Experimental Therapeutics August 1, 1999, 290 (2) 551-560;
Research ArticleArticle
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles
C.-C. Chan, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, A. W. Ford-Hutchinson, M. J. Forrest, J. Y. Gauthier, R. Gordon, M. Gresser, J. Guay, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mancini, G. P. O’Neill, M. Ouellet, D. Patrick, M. D. Percival, H. Perrier, P. Prasit, I. Rodger, P. Tagari, M. Therien, P. Vickers, D. Visco, Z. Wang, J. Webb, E. Wong, L.-J. Xu, R. N. Young, R. Zamboni and D. Riendeau
Journal of Pharmacology and Experimental Therapeutics August 1, 1999, 290 (2) 551-560;
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement